·564·中华心血管病杂志2020年7月第48卷第7期ChinJCardiol,July2020,Vol.48,No.7
[41]RubboliA,SaiaF,SciahbasiA,etal.Twelve‐monthfibrillation:theELIMINATE‐AFtrial[J].EurHeartJ,2019,
outcomeofpatientswithanestablishedindicationfor40(36):3013‐3021.DOI:10.1093/eurheartj/ehz190.
oralanticoagulationundergoingcoronaryarterystenting[54]CalkinsH,WillemsS,GerstenfeldEP,etal.Uninterrupted
andstratifiedbythebaselineriskofbleeding:insightsdabigatranversuswarfarinforablationinatrial
fromthewarfarinandcoronarystenting(War‐Stent)fibrillation[J].NEnglJMed,2017,376(17):1627‐1636.
registry[J].CardiovascRevascMed,2017,18(6):425‐430.DOI:10.1056/NEJMoa1701005.
DOI:10.1016/j.carrev.2017.03.015.[55]CappatoR,MarchlinskiFE,HohnloserSH,etal.
[42]SambolaA,MutuberríaM,GarcíaDelBlancoB,etal.Uninterruptedrivaroxabanvs.uninterruptedvitaminK
Effectsoftripletherapyinpatientswithnon‐valvularantagonistsforcatheterablationinnon‐valvularatrial
atrialfibrillationundergoingpercutaneouscoronaryfibrillation[J].EurHeartJ,2015,36(28):1805‐1811.DOI:
interventionregardingthromboembolicriskstratification10.1093/eurheartj/ehv177.
[J].CircJ,2016,80(2):354‐362.DOI:10.1253/circj.[56]AndreottiF,RoccaB,HustedS,etal.Antithrombotic
CJ‐15‐0923.therapyintheelderly:expertpositionpaperofthe
[43]SarafoffN,MartischnigA,WealerJ,etal.TripletherapyEuropeanSocietyofCardiologyWorkingGroupon
withaspirin,prasugrel,andvitaminKantagonistsinThrombosis[J].EurHeartJ,2015,36(46):3238‐3249.
patientswithdrug‐elutingstentimplantationandanDOI:10.1093/eurheartj/ehv304.
indicationfororalanticoagulation[J].JAmCollCardiol,[57]NochaiwongS,RuengornC,AwiphanR,etal.Efficacyand
2013,61(20):2060‐2066.DOI:10.1016/j.jacc.2013.safetyofwarfarinindialysispatientswithatrial
02.036.fibrillation:asystematicreviewandmeta‐analysis[J].
[44]HanY,GuoJ,ZhengY,etal.BivalirudinvsheparinwithorOpenHeart,2016,3(1):e000441.DOI:10.1136/
withouttirofibanduringprimarypercutaneouscoronaryopenhrt‐2016‐000441.
interventioninacutemyocardialinfarction:theBRIGHT[58]SiontisKC,ZhangX,EckardA,etal.Outcomesassociated
randomizedclinicaltrial[J].JAMA,2015,313(13):withapixabanuseinpatientswithend‐stagekidney
1336‐1346.DOI:10.1001/jama.2015.2323.diseaseandatrialfibrillationintheUnitedStates[J].
[45]BangaloreS,TokluB,KotwalA,etal.AnticoagulantCirculation,2018,138(15):1519‐1529.DOI:10.1161/
therapyduringprimarypercutaneouscoronaryCIRCULATIONAHA.118.035418.
interventionforacutemyocardialinfarction:a[59]ColemanCI,KreutzR,SoodNA,etal.Rivaroxabanversus
meta‐analysisofrandomizedtrialsintheeraofstentswarfarininpatientswithnonvalvularatrialfibrillation
andP2Y12inhibitors[J].BMJ,2014,349:g6419.DOI:andseverekidneydiseaseorundergoinghemodialysis[J].
10.1136/bmj.g6419.AmJMed,2019,132(9):1078‐1083.DOI:10.1016/j.
[46]AndòG,CapodannoD.Radialaccessreducesmortalityinamjmed.2019.04.013.
patientswithacutecoronarysyndromes:resultsfroman[60]KoskinasKC,R?berL,ZanchinT,etal.Clinicalimpactof
updatedtrialsequentialanalysisofrandomizedtrials[J].gastrointestinalbleedinginpatientsundergoingpercutaneous
JACCCardiovascInterv,2016,9(7):660‐670.DOI:coronaryinterventions[J].CircCardiovascInterv,2015,8(5):
10.1016/j.jcin.2015.12.008.e002053.DOI:10.1161/CIRCINTERVENTIONS.114.002053.
[47]SteffelJ,VerhammeP,PotparaTS,etal.The2018[61]HamonM,LemesleG,TricotO,etal.Incidence,source,
EuropeanHeartRhythmAssociationPracticalGuideondeterminants,andprognosticimpactofmajorbleedingin
theuseofnon‐vitaminKantagonistoralanticoagulantsinoutpatientswithstablecoronaryarterydisease[J].JAm
patientswithatrialfibrillation[J].EurHeartJ,2018,CollCardiol,2014,64(14):1430‐1436.DOI:10.1016/j.
39(16):1330‐1393.DOI:10.1093/eurheartj/ehy136.jacc.2014.07.957.
[48]YasudaS,KaikitaK,AkaoM,etal.Antithrombotictherapy[62]抗栓治疗消化道损伤防治专家组.抗栓治疗消化道损伤防治
foratrialfibrillationwithstablecoronarydisease[J].N中国专家建议(2016·北京)[J].中华内科杂志,2016,55(7):
EnglJMed,2019,381(12):1103‐1113.DOI:10.1056/564‐567.DOI:10.3760/cma.j.issn.0578‐1426.2016.07.020.
NEJMoa1904143.[63]TomaselliGF,MahaffeyKW,CukerA,etal.2017ACC
[49]KnuutiJ,WijnsW,SarasteA,etal.2019ESCGuidelinesexpertconsensusdecisionpathwayonmanagementof
forthediagnosisandmanagementofchroniccoronarybleedinginpatientsonoralanticoagulants:areportof
syndromes[J].EurHeartJ,2020,41(3):407‐477.DOI:theAmericanCollegeofCardiologyTaskForceonExpert
10.1093/eurheartj/ehz425.ConsensusDecisionPathways[J].JAmCollCardiol,2017,
[50]国家卫生计生委合理用药专家委员会,中国药师协会.冠70(24):3042‐3067.DOI:10.1016/j.jacc.2017.09.1085.
心病合理用药指南(第2版)[J].中国医学前沿杂志(电子[64]vanRynJ,StangierJ,HaertterS,etal.Dabigatran
版),2018,10(6):1‐130.DOI:10.12037/YXQY.2018.06-01.etexilate-anovel,reversible,oraldirectthrombin
[51]冠状动脉旁路移植术围术期抗血小板治疗共识专家组.冠inhibitor:interpretationofcoagulationassaysand
状动脉旁路移植术围术期抗血小板治疗专家共识[J].中华reversalofanticoagulantactivity[J].ThrombHaemost,
胸心血管外科杂志,2016,32(1):1‐8.DOI:10.3760/cma.j.2010,103(6):1116‐1127.DOI:10.1160/TH09‐11‐0758.
issn.1001‐4497.2016.01.001.[65]SiegalDM,CurnutteJT,ConnollySJ,etal.Andexanetalfafor
[52]KirchhofP,HaeuslerKG,BlankB,etal.ApixabaninthereversaloffactorXainhibitoractivity[J].NEnglJMed,
patientsatriskofstrokeundergoingatrialfibrillation2015,373(25):2413‐2424.DOI:10.1056/NEJMoa1510991.
ablation[J].EurHeartJ,2018,39(32):2942‐2955.DOI:[66]ConnollySJ,MillingTJ,EikelboomJW,etal.Andexanetalfa
10.1093/eurheartj/ehy176.foracutemajorbleedingassociatedwithfactorXa
[53]HohnloserSH,CammJ,CappatoR,etal.Uninterruptedinhibitors[J].NEnglJMed,2016,375(12):1131‐1141.
edoxabanvs.vitaminKantagonistsforablationofatrialDOI:10.1056/NEJMoa1607887. |
|
